Skip to main content
JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD. logo

JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688670 ISIN · CNE100004NR4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 448 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688670

About JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD.

http://www.gdkbio.com/

Jiangsu GDK Biological Technology Co., Ltd. specializes in the research, development, and manufacturing of high-quality laboratory consumables and life science research tools. The company operates advanced production facilities, including Class 100,000 cleanrooms, to ensure products are free from DNase, RNase, and pyrogens. Its core product portfolio includes precision pipette tips, PCR consumables, centrifuge tubes, cell culture vessels, and deep-well plates. A significant focus is placed on automated workstation consumables compatible with leading liquid handling systems. Utilizing high-precision mold technology and medical-grade raw materials, the company provides reliable solutions for clinical diagnostics, molecular biology, and pharmaceutical research. GDK maintains rigorous quality management standards, holding ISO 9001 and ISO 13485 certifications to meet the demands of global biotechnology and healthcare sectors.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于江苏金迪克生物技术股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) from a law firm assessing the legality of the company’s 2025 annual shareholders meeting procedures, attendance, and voting results. It is not the AGM materials themselves, nor a full financial report, but rather a certification/attestation by counsel. Under the “Certification Rule,” such letters are classified as general regulatory filings (RNS).
2026-05-14 Chinese
江苏金迪克生物技术股份有限公司关于完成董事会换届选举暨聘任高级管理人员、审计部负责人的公告
Board/Management Information Classification · 93% confidence The document is an official announcement by the company’s board of directors detailing the completion of board member elections and the appointment of senior management and the audit department head. It does not provide financial results or discuss filings, but rather communicates changes in directors and management personnel. This corresponds to Board/Management Information (MANG).
2026-05-14 Chinese
江苏金迪克生物技术股份有限公司2025年年度股东会会议资料
Regulatory Filings
2026-05-06 Chinese
中信证券股份有限公司关于江苏金迪克生物技术股份有限公司部分募集资金投资项目延期的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion from a sponsoring institution (中信证券股份有限公司) regarding the delay in certain investment projects funded by raised capital for 江苏金迪克生物技术股份有限公司. It references regulatory rules related to fundraising and investment project management, details the amount and use of raised funds, and confirms compliance with relevant laws and procedures. The document does not contain financial statements or quarterly/yearly financial results but is a regulatory compliance and verification report related to capital use and project progress. It is not an annual report, earnings release, or management discussion but a regulatory filing about fundraising project delays and compliance. The document length is about 2805 characters, relatively short and focused on a specific regulatory compliance matter. Therefore, it fits best under Regulatory Filings (RNS) as a compliance and verification announcement rather than a financial report or capital update filing.
2026-04-22 Chinese
江苏金迪克生物技术股份有限公司关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jiangsu Jindike Biotechnology Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board meeting approval, the amount and purpose of the cash management, compliance with regulatory rules, risk control measures, and includes a sponsor's verification opinion. The document does not contain financial statements or detailed financial performance data but is a disclosure about the company's financing fund usage and management decisions. It is not an annual report, interim report, earnings release, or audit report. It is a regulatory announcement about capital usage and management of raised funds, fitting the category of Capital/Financing Update (CAP). The document length is 3413 characters, which is relatively short but contains substantive information about capital management, not just a brief notice or report publication announcement. Therefore, the best classification is CAP with high confidence.
2026-04-22 Chinese
江苏金迪克生物技术股份有限公司董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm (auditor) for the company's annual audit work for the year 2025. It details the auditor's qualifications, the process of reappointment, communications with the auditor, and an overall evaluation of the auditor's performance in relation to the annual audit. The document references the 2025 annual audit and the audit committee's oversight role but does not contain the actual audited financial statements or the full annual report itself. The document is about the audit process and the audit committee's supervisory activities, which aligns with the definition of an Audit Report / Information (AR) filing. The document length is 1791 characters, which is relatively short but contains substantive content about audit supervision rather than just an announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information).
2026-04-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.